ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN PHARMACEUTICAL RESEARCH: TRANSFORMING DRUG DISCOVERY, FORMULATION DEVELOPMENT, AND QUALITY ASSURANCE

Artificial intelligence (AI) and machine learning (ML) are revolutionizing pharmaceutical research by transforming conventional empirical methodologies into predictive, data-driven frameworks. Across drug discovery, AI facilitates rapid target identification through genomic and proteomic data mining, accelerates virtual screening and lead optimization, enables de novo molecular design using generative models, and improves protein structure prediction through advanced deep learning systems such as AlphaFold developed by DeepMind. In formulation development, AI enhances preformulation prediction, excipient compatibility assessment, dissolution modeling, and design space optimization under Quality by Design principles. Integration of ML with process analytical technology (PAT), digital twins, and predictive maintenance systems strengthens manufacturing efficiency and real-time quality assurance. Furthermore, AI-driven ADMET prediction and drug repurposing strategies reduce attrition rates and development costs while supporting personalized medicine initiatives. Despite these advancements, challenges related to data quality, model interpretability, regulatory validation, and ethical governance persist. Addressing these limitations through standardized validation frameworks and explainable AI approaches is essential for sustainable implementation. Overall, AI represents a paradigm shift in pharmaceutical sciences, offering accelerated development timelines, cost efficiency, and enhanced therapeutic precision. Keywords: Artificial Intelligence; Machine Learning; Deep Learning; Drug Discovery; De Novo Drug Design; AlphaFold; ADMET Prediction; Formulation Optimization; Process Analytical Technology; Digital Twins; Quality Assurance; Precision Medicine